Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

CD200-expressing human basal cell carcinoma cells initiate tumor growth

Colmont, Chantal Sophie, Ben Ketah, Antisar, Reed, Simon Huw ORCID: https://orcid.org/0000-0002-4711-0560, Hawk, Nga V., Telford, William G., Ohyama, Manabu, Udeye, Mark C., Yee, Carole L., Vogel, Jonathan C. and Patel, Girish Khandubhai 2013. CD200-expressing human basal cell carcinoma cells initiate tumor growth. Proceedings of the National Academy of Sciences of the United States of America 110 (4) , pp. 1434-1439. 10.1073/pnas.1211655110

Full text not available from this repository.

Abstract

Smoothened antagonists directly target the genetic basis of human basal cell carcinoma (BCC), the most common of all cancers. These drugs inhibit BCC growth, but they are not curative. Although BCC cells are monomorphic, immunofluorescence microscopy reveals a complex hierarchical pattern of growth with inward differentiation along hair follicle lineages. Most BCC cells express the transcription factor KLF4 and are committed to terminal differentiation. A small CD200+ CD45− BCC subpopulation that represents 1.63 ± 1.11% of all BCC cells resides in small clusters at the tumor periphery. By using reproducible in vivo xenograft growth assays, we determined that tumor initiating cell frequencies approximate one per 1.5 million unsorted BCC cells. The CD200+ CD45− BCC subpopulation recreated BCC tumor growth in vivo with typical histological architecture and expression of sonic hedgehog-regulated genes. Reproducible in vivo BCC growth was achieved with as few as 10,000 CD200+ CD45− cells, representing ∼1,500-fold enrichment. CD200− CD45− BCC cells were unable to form tumors. These findings establish a platform to study the effects of Smoothened antagonists on BCC tumor initiating cell and also suggest that currently available anti-CD200 therapy be considered, either as monotherapy or an adjunct to Smoothened antagonists, in the treatment of inoperable BCC.

Item Type: Article
Date Type: Publication
Status: Published
Schools: Biosciences
European Cancer Stem Cell Research Institute (ECSCRI)
Medicine
Subjects: Q Science > QH Natural history > QH301 Biology
R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
R Medicine > RL Dermatology
Uncontrolled Keywords: mouse model; skin cancer
Publisher: National Academy of Sciences
ISSN: 1091-6490
Last Modified: 25 Oct 2022 08:13
URI: https://orca.cardiff.ac.uk/id/eprint/51909

Citation Data

Cited 28 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item Edit Item